¹æ±¤¾Ï Ä¡·á ¹× Áø´Ü ½ÃÀå ¿¹Ãø(-2030³â) : ¾Ï À¯Çü, ¿ä¹ý, Áø´Ü, Ä¡·á ½ºÅ×ÀÌÁö, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº° ¼¼°è ºÐ¼®
Bladder Cancer Therapeutics and Diagnostics Market Forecasts to 2030 - Global Analysis by Cancer Type, Therapeutics, Diagnostics, Treatment Stage, End User and By Geography
»óǰÄÚµå : 1636752
¸®¼­Ä¡»ç : Stratistics Market Research Consulting
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200+ Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,150 £Ü 6,004,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,596,000
PDF (2-5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ±îÁö °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,350 £Ü 9,187,000
PDF & Excel (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ±îÁö °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,500 £Ü 10,851,000
PDF & Excel (Global Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 10ȸ±îÁö °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Stratistics MRC¿¡ µû¸£¸é, ¼¼°è ¹æ±¤¾Ï Ä¡·á ¹× Áø´Ü ½ÃÀåÀº 2024³â 4¾ï 7,150¸¸ ´Þ·¯ ±Ô¸ðÀ̸ç, ¿¹Ãø ±â°£ µ¿¾È ¿¬Æò±Õ 8.9%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 7¾ï 8,640¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹æ±¤¾Ï Ä¡·á ¹× Áø´ÜÀº ¹æ±¤¾ÏÀ» °ü¸®ÇÏ°í ½Äº°ÇÏ´Â µ¥ »ç¿ëµÇ´Â ÀÇ·á Ä¡·á ¹× ±â¼úÀÔ´Ï´Ù. Ä¡·á¿¡´Â ¼ö¼ú, È­Çпä¹ý, ¸é¿ª¿ä¹ý, ¹æ»ç¼±¿ä¹ý, Ç¥ÀûÄ¡·á µî ¾Ï¼¼Æ÷¸¦ Á×À̰ųª Áõ½ÄÀ» ¾ïÁ¦Çϱâ À§ÇÑ ´Ù¾çÇÑ Ä¡·á¹ýÀÌ Æ÷ÇԵ˴ϴÙ. Áø´ÜÇп¡´Â ¼Òº¯ °Ë»ç, ¹æ±¤°æ °Ë»ç, ¿µ»ó Áø´Ü(CT ½ºÄµ, ÃÊÀ½ÆÄ °Ë»ç µî), »ý°Ë µî ¾ÏÀ» ¹ß°ßÇÏ°í º´±â¸¦ ºÐ·ùÇϱâ À§ÇÑ ´Ù¾çÇÑ °Ë»ç¿Í ½Ã¼úÀÌ Æ÷ÇԵ˴ϴÙ. »ýÁ¸À²À» ³ôÀ̱â À§Çؼ­´Â Á¶±â ¹ß°ß°ú °í±Þ Ä¡·á°¡ ÇʼöÀûÀ̸ç, ÇöÀç ÁøÇà ÁßÀÎ ¸ÂÃãÇü ÀÇ·á ¿¬±¸´Â Ä¡·á¿Í Áø´Ü Á¢±Ù¹ý ¸ðµÎ¿¡ ´ëÇÑ È¿°ú¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù.

¹Ì±¹¾ÏÇùȸ¿¡ µû¸£¸é, 2022³â¿¡´Â ¹Ì±¹¿¡¼­ ¾à 81,180¸íÀÇ ¹æ±¤¾Ï ȯÀÚ°¡ »õ·Î ¹ß»ýÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹æ±¤¾Ï ¹ß»ý·ü Áõ°¡

¹æ±¤¾Ï ¹ßº´·üÀÇ Áõ°¡´Â ¹æ±¤¾Ï Ä¡·á ¹× Áø´Ü ½ÃÀåÀ» ±¤¹üÀ§ÇÏ°Ô °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¹æ±¤¾Ï Áø´ÜÀ» ¹Þ´Â ȯÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¿µ»ó Áø´Ü, ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç µî ÷´Ü Áø´Ü µµ±¸¿Í Ç¥ÀûÄ¡·á, ¸é¿ªÄ¡·á, È­Çпä¹ý µî Çõ½ÅÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¶±â ¹ß°ß°ú ¸ÂÃã Ä¡·á¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϸ鼭 ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖÀ¸¸ç, ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¿Í Á¦¾à»çµéÀº ¹æ±¤¾Ï À¯º´·ü Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ »õ·Î¿î Ä¡·á¹ý°ú Áø´Ü ¼Ö·ç¼ÇÀ» °³¹ßÇÏ´Â µ¥ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù.

³ôÀº Ä¡·áºñ

¹æ±¤¾Ï Ä¡·á¿Í Áø´Ü¿¡ ¸¹Àº ºñ¿ëÀÌ µé±â ¶§¹®¿¡ ƯÈ÷ ÁßÀú¼Òµæ ±¹°¡¿¡¼­ ¹æ±¤¾Ï Ä¡·á¿Í Áø´ÜÀº ½ÃÀå È®´ë¿¡ Å« À庮ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¸é¿ª¿ä¹ýÀ̳ª Ç¥Àû Ä¡·áÁ¦¿Í °°Àº ÃֽŠÀǾàǰÀº °í°¡À̱⠶§¹®¿¡ ȯÀÚµéÀÇ Á¢±Ù¼ºÀ̳ª ±¸¸Å °¡´É °¡°ÝÀÌ Á¦ÇÑÀûÀÔ´Ï´Ù. ÀÌ ¹®Á¦´Â ½Å¼ÓÇÑ Áø´Ü°ú È¿À²ÀûÀÎ Ä¡·á¸¦ ¹æÇØÇÏ´Â º¸Çè Àû¿ë ¹× º»ÀÎ ºÎ´ã±Ý °ÝÂ÷·Î ÀÎÇØ ´õ¿í ½É°¢ÇØÁ® ȯÀÚÀÇ Ä¡·á °á°ú¸¦ Áö¿¬½ÃŰ°í ´õ ±¤¹üÀ§ÇÑ ½ÃÀå µµÀÔÀ» ¹æÇØÇϰí ÀÖ½À´Ï´Ù.

Á¶±â ¹ß°ß ±â¼ú

Á¶±â ¹ß°ß ±â¼úÀº Á¶±â Áø´ÜÀ» °¡´ÉÇÏ°Ô Çϰí, Ä¡·á °á°ú¸¦ °³¼±Çϰí, »ç¸Á·üÀ» ³·ÃãÀ¸·Î½á ¹æ±¤¾Ï Ä¡·á ¹× Áø´Ü ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¾×ü »ý°Ë, ¿µ»ó Áø´ÜÀÇ ¹ßÀü, ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç µîÀÇ ±â¼úÀº Ãʱ⠴ܰ迡¼­ ¾ÏÀ» ½Äº°ÇÒ ¼ö ÀÖ°Ô ÇØ °³ÀÎÈ­µÈ Ä¡·á °èȹÀ» ¼ö¸³ÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. À̸¦ ÅëÇØ Ä¡·áÀÇ È¿À²¼ºÀ» ³ôÀÌ°í ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϸç ÀÇ·á ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±× °á°ú, ¹æ±¤¾Ï Áø´Ü ¹× Ä¡·á ½ÃÀåÀº ÀÌ·¯ÇÑ ±â¼ú Çõ½Å¿¡ ÈûÀÔ¾î ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

Ä¡·á ºÎÀÛ¿ë

È­Çпä¹ý, ¸é¿ª¿ä¹ý, ¹æ»ç¼± ¿ä¹ý µî ¹æ±¤¾Ï Ä¡·áÀÇ ºÎÀÛ¿ëÀº ȯÀÚÀÇ ¼øÀÀµµ¿Í Ä¡·á È¿°ú¸¦ ¶³¾î¶ß·Á ½ÃÀå ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù. ÇÇ·Î, ¸Þ½º²¨¿ò, ¸é¿ª °ü·Ã ¹®Á¦´Â »îÀÇ ÁúÀ» ¶³¾î¶ß¸®°í Ä¡·á¸¦ Áß´ÜÇϰųª ¿¬±âÇÏ°Ô ¸¸µå´Â ºÎÀÛ¿ëÀÇ ÇÑ ¿¹ÀÔ´Ï´Ù. ȯÀÚ¿Í ÀÇ·á Àü¹®°¡µéÀÇ ¿ì·Á´Â ÀϺΠġ·á¹ýÀÇ º¸±ÞÀ» ´ÊÃß°í Àüü ¹æ±¤¾Ï Ä¡·á ¹× Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

COVID-19ÀÇ ¿µÇâ:

COVID-19´Â ¼±ÅÃÀû ¼ö¼úÀ» Áö¿¬½Ã۰í, ȯÀÚ ¹æ¹®À» ÁÙÀ̸ç, ÀÓ»ó½ÃÇèÀ» Á¦ÇÑÇÏ´Â µî ¹æ±¤¾Ï Ä¡·á ¹× Áø´Ü ½ÃÀåÀ» È¥¶õ¿¡ ºü¶ß·È½À´Ï´Ù. Áø´Ü °Ë»ç¿Í Ä¡·áÀÇ °¡¿ë¼ºÀÌ ¿µÇâÀ» ¹Þ¾Æ Ä¡·á ¿¬±â·Î À̾îÁ³½À´Ï´Ù. ±×·¯³ª ÆÒµ¥¹Í ÀÌÈÄ ¾Ï Ä¡·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ¿ø°ÝÁø·á¿Í ¿ø°Ý Áø´ÜÀÇ Ã¤ÅÃÀÌ °¡¼ÓÈ­µÇ¸é¼­ ½ÃÀå ȸº¹À» µÞ¹ÞħÇϰí ÀÖÀ¸¸ç, Àå±âÀûÀ¸·Î Çõ½ÅÀûÀÎ Ä¡·á¹ý°ú Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È ¹æ±¤°æ °Ë»ç ºÎ¹®ÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹æ±¤ ³»½Ã°æ °Ë»ç´Â ¹æ±¤ ³»º®À» Á÷Á¢ º¼ ¼ö ÀÖ°í Á¾¾ç°ú ÀÌ»óÀ» ½Äº°ÇÏ´Â µ¥ µµ¿òÀÌ µÇ±â ¶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È °¡Àå Å« ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áø´Ü µµ±¸´Â »ý°ËÀ» Áö¿øÇÏ°í º¸´Ù Á¤È®ÇÑ Ä¡·á °èȹÀ» ¼ö¸³ÇÏ´Â µ¥ ±â¿©ÇÕ´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ¹æ±¤¾Ï ȯÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó Á¶±â Áø´Ü ¹× ÈÄ¼Ó Ä¡·á °³ÀÔ¿¡¼­ ¹æ±¤°æ °Ë»çÀÇ ¿ªÇÒÀº Áø´Ü ¹× Ä¡·á ºÐ¾ß ¸ðµÎ¿¡¼­ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È ¹æ»ç¼± Ä¡·á ºÐ¾ß°¡ °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹æ»ç¼± Ä¡·á ºÐ¾ß´Â »ýÁ¸À²À» ³ôÀ̱â À§ÇØ ¼ö¼úÀ̳ª È­Çпä¹ý°ú º´ÇàÇÏ´Â °æ¿ì°¡ ¸¹¾Æ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿µ»óÀ¯µµ¹æ»ç¼±Ä¡·á(IGRT), ¼¼±âº¯Á¶¹æ»ç¼±Ä¡·á(IMRT) µî ¹æ»ç¼± Ä¡·á ±â¼úÀÇ ¹ßÀüÀ¸·Î Á¤È®µµ°¡ Çâ»óµÇ°í ºÎÀÛ¿ëÀÌ °¨¼ÒÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº Ä¡·á È¿°ú ¸ð´ÏÅ͸µ ¹× Àç¹ß ¹ß°ßÀ» À§ÇÑ Ã·´Ü Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ÇÔ²² ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

°¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª:

ºÏ¹Ì´Â ¹æ±¤¾Ï À¯º´·ü Áõ°¡, Áø´Ü µµ±¸ÀÇ °³¼±, ÁýÁßÄ¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àα¸ °í·ÉÈ­¿Í Èí¿¬À² Áõ°¡´Â ¾Ï ¹ß»ý·ü Áõ°¡·Î À̾îÁö´Â Áß¿äÇÑ º¯¼öÀÔ´Ï´Ù. ¶ÇÇÑ, ºñħ½ÀÀû Áø´Ü ±â¼ú ¹× ¸é¿ª¿ä¹ýÀÇ ¹ßÀü, ÀÇ·á ¼­ºñ½º Á¢±Ù¼º ¹× ¿¬±¸ ÀÚ±ÝÀÇ Áõ°¡´Â ÀÌ Áö¿ªÀÇ ½ÃÀå È®ÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª:

¾Æ½Ã¾ÆÅÂÆò¾çÀº ¾Ï ¹ßº´·ü Áõ°¡, ÇコÄɾ ´ëÇÑ ÀÎ½Ä Áõ°¡, Áø´Ü ±â¼ú ¹ßÀü, Ç¥Àû Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀÇ ÀÇ·á ÀÎÇÁ¶ó È®´ë¿Í ÃÖ¼Òħ½À ¼ö¼úÀÇ Ã¤Åõµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »õ·Î¿î ¹ÙÀÌ¿À¸¶Ä¿¿Í ¸é¿ªÄ¡·á¿¡ ´ëÇÑ ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖÀ¸¸ç, ÷´Ü Ä¡·á¹ý¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÊ¿¡ µû¶ó ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­ ¹æ±¤¾ÏÀÇ Çõ½ÅÀûÀÎ Áø´Ü ¹× Ä¡·á ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¹«·á Ä¿½ºÅ͸¶ÀÌ¡ ¼­ºñ½º

º» º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½°ú °°Àº ¹«·á ¸ÂÃãÈ­ ¿É¼Ç Áß Çϳª¸¦ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù:

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

Á¦4Àå Porter's Five Forces ºÐ¼®

Á¦5Àå ¼¼°èÀÇ ¹æ±¤¾Ï Ä¡·á ¹× Áø´Ü ½ÃÀå : ¾Ï À¯Çüº°

Á¦6Àå ¼¼°èÀÇ ¹æ±¤¾Ï Ä¡·á ¹× Áø´Ü ½ÃÀå : ¿ä¹ýº°

Á¦7Àå ¼¼°èÀÇ ¹æ±¤¾Ï Ä¡·á ¹× Áø´Ü ½ÃÀå : Áø´Üº°

Á¦8Àå ¼¼°èÀÇ ¹æ±¤¾Ï Ä¡·á ¹× Áø´Ü ½ÃÀå : Ä¡·á ½ºÅ×ÀÌÁöº°

Á¦9Àå ¼¼°èÀÇ ¹æ±¤¾Ï Ä¡·á ¹× Áø´Ü ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå ¼¼°èÀÇ ¹æ±¤¾Ï Ä¡·á ¹× Áø´Ü ½ÃÀå : Áö¿ªº°

Á¦11Àå ÁÖ¿ä ¹ßÀü

Á¦12Àå ±â¾÷ °³¿ä

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

According to Stratistics MRC, the Global Bladder Cancer Therapeutics and Diagnostics Market is accounted for $471.5 million in 2024 and is expected to reach $786.4 million by 2030 growing at a CAGR of 8.9% during the forecast period. Bladder cancer therapies and diagnostics are the medical treatments and technologies used to manage and identify bladder cancer. Therapeutics includes a range of treatments such as surgery, chemotherapy, immunotherapy, radiation therapy, and targeted therapy, aimed at killing cancer cells or preventing their growth. Diagnostics involve various tests and procedures, such as urine tests, cystoscopy, imaging (e.g., CT scans, ultrasounds), and biopsy, to detect and stage the cancer. Early detection and advanced treatments are crucial for improving survival rates, and ongoing research in personalized medicine is enhancing the effectiveness of both therapeutic and diagnostic approaches.

According to the American Cancer Society, in 2022, there are around 81,180 new cases of bladder cancer 61,700 in men and 19,480 in women in the United States.

Market Dynamics:

Driver:

Rising Incidence of Bladder Cancer

The rising incidence of bladder cancer is extensively driving the bladder cancer therapeutics and diagnostics market. As more individuals are diagnosed, there is increased demand for advanced diagnostic tools, such as imaging and biomarker testing, and innovative treatment options, including targeted therapies, immunotherapies, and chemotherapy. This growing need for early detection and personalized treatments is propelling market growth, with healthcare providers and pharmaceutical companies focusing on developing novel therapies and diagnostic solutions to address the rising prevalence of bladder cancer.

Restraint:

High Treatment Costs

The high expense of bladder cancer diagnostics and treatments is a significant barrier to market expansion, especially in low- and middle-income nations. Patient access and affordability are restricted by the high cost of modern medicines, such as immunotherapies and targeted treatments. This problem is made worse by gaps in insurance coverage and out-of-pocket costs, which obstruct prompt diagnosis and efficient treatment, delaying patient results and impeding wider market adoption.

Opportunity:

Early Detection Technologies

Early detection technologies are significantly impacting the bladder cancer therapeutics and diagnostics market by enabling earlier diagnosis, improving treatment outcomes, and reducing mortality rates. Technologies such as liquid biopsy, imaging advancements, and biomarker testing allow for the identification of cancer at its initial stages, leading to personalized treatment plans. This enhances the efficiency of therapies, minimizes side effects, and reduces healthcare costs. As a result, the market for bladder cancer diagnostics and treatments is expanding rapidly, driven by these innovations.

Threat:

Side Effects of Treatments

The adverse effects of bladder cancer therapies such as chemotherapy, immunotherapy, and radiation impede market growth by decreasing patient adherence and treatment efficacy. Fatigue, nausea, and immune-related problems are examples of adverse effects that might lower quality of life and cause therapy to be stopped or postponed. Patients and healthcare professionals become concerned about this, which slows the uptake of some treatments and hinders the market's overall growth for bladder cancer treatments and diagnostics.

Covid-19 Impact:

The COVID-19 pandemic disrupted the Bladder Cancer Therapeutics and Diagnostics Market by delaying elective surgeries, reducing patient visits, and limiting clinical trials. Diagnostic testing and treatment availability were impacted, leading to treatment postponements. However, the growing focus on cancer care post-pandemic, along with accelerated adoption of telemedicine and remote diagnostics has supported market recovery, driving demand for innovative therapies and diagnostic solutions in the long term.

The cystoscopy segment is expected to be the largest during the forecast period

The cystoscopy segment is expected to be the largest during the forecast period as it allows for direct visualization of the bladder lining, aiding in the identification of tumors or abnormalities. This diagnostic tool supports biopsy procedures, contributing to more precise treatment planning. As bladder cancer cases increase globally, cystoscopy's role in early-stage diagnosis and subsequent therapeutic interventions is driving growth in both the diagnostics and therapeutics sectors.

The radiotherapy segment is expected to have the highest CAGR during the forecast period

The radiotherapy segment is expected to have the highest CAGR during the forecast period because it is often combined with surgery or chemotherapy to improve survival rates. Advances in radiotherapy techniques, such as image-guided radiation therapy (IGRT) and intensity-modulated radiation therapy (IMRT), have enhanced precision, reducing side effects. These innovations are driving the market, along with the increasing demand for advanced diagnostic tools to monitor treatment efficacy and detect recurrence.

Region with largest share:

North America is anticipated to hold the largest market share during the forecast period because of the rising prevalence of bladder cancer, improvements in diagnostic tools, and the expanding need for focused treatments. The aging of the population and the increase in smoking are important variables that lead to increased cancer rates. Furthermore, advances in non-invasive diagnostic technologies and immunotherapies, as well as increased healthcare access and research funding, are driving market expansion in the area.

Region with highest CAGR:

Asia Pacific is anticipated to witness the highest CAGR over the forecast period owing to rising cancer incidences, increasing healthcare awareness, advancements in diagnostic technologies, and growing demand for targeted therapies. The region's expanding healthcare infrastructure and the adoption of minimally invasive procedures also contribute to market growth. Additionally, ongoing research into novel biomarkers and immunotherapies, along with enhanced access to advanced treatments, are boosting the adoption of innovative diagnostic and therapeutic solutions for bladder cancer in Asia-Pacific.

Key players in the market

Some of the key players in Bladder Cancer Therapeutics and Diagnostics market include Abbott Laboratories, AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Endo Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., GlaxoSmithKline PLC, Hoffmann-La Roche AG, Johnson & Johnson, Kaiser Permanente, Merck & Co., Inc., Novartis International AG, Pacific Edge Limited, Pfizer Inc. and Sanofi S.A.

Key Developments:

In September 2024, iCardio.ai announced collaboration with Abbott to develop AI applications for the medtech giant's imaging technologies.

In August 2024, Abbott announced a unique global partnership with Medtronic to collaborate on an integrated continuous glucose monitoring (CGM) system based on Abbott's most advanced, world-leading1 FreeStyle Libre technology that will connect with Medtronic's automated insulin delivery (AID) and smart insulin pen systems.

In August 2024, The American Diabetes Association and Abbott recently announced a collaboration to better understand the nutritional needs of people living with diabetes, obesity, and metabolic dysfunction and how nutrition formulas can support those needs and overall health.

Cancer Types Covered:

Therapeutics Covered:

Diagnostics Covered:

Treatment Stages Covered:

End Users Covered:

Regions Covered:

What our report offers:

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Table of Contents

1 Executive Summary

2 Preface

3 Market Trend Analysis

4 Porters Five Force Analysis

5 Global Bladder Cancer Therapeutics and Diagnostics Market, By Cancer Type

6 Global Bladder Cancer Therapeutics and Diagnostics Market, By Therapeutics

7 Global Bladder Cancer Therapeutics and Diagnostics Market, By Diagnostics

8 Global Bladder Cancer Therapeutics and Diagnostics Market, By Treatment Stage

9 Global Bladder Cancer Therapeutics and Diagnostics Market, By End User

10 Global Bladder Cancer Therapeutics and Diagnostics Market, By Geography

11 Key Developments

12 Company Profiling

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â